Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers
NCT05532293Phase 1Completed
- Sponsor
- Godavari Biorefineries
- Start
- Dec 2022
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing MSP008-22 with Placebo (2 arms). Primary endpoints: Number of participants with adverse events, Incidence of serious adverse events and 5 more. Started Dec 2022; status: completed.
02
Drugs
MSP008-22
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05532293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532293.